Today on Drug Discovery & Development
Regulatory strategy reimagined: Three trends accelerating drug development
Is AI a risk or an opportunity? Is regulatory divergence a barrier or a catalyst for innovation? The answer depends on how prepared and how agile your organisation is. As regulatory frameworks shift beneath our feet, the question facing every drug developer is not ‘if’ but ‘how’ these macro trends will disrupt their strategy. In…
Trump administration makes deal with Eli Lilly, Novo Nordisk to lower GLP-1 prices
On Thursday, the Trump administration announced agreements with Eli Lilly and Novo Nordisk to reduce the prices of the companies’ GLP-1 drugs for Americans. Under the agreements, Ozempic and Wegovy will be sold at $350 per month and Zepbound for an average of $346 per month, depending on dose, when purchased through TrumpRx, a platform…
Drug Discovery and Development See More >
Sai Life Sciences to double process R&D capacity with new Hyderabad facility
New CMC Process R&D center will add peptide and oligo-intermediate capabilities, expand analytical and formulation labs and target completion by September 2026. Sai Life Sciences plans to build a 100,000-sq-ft CMC Process R&D center at its integrated R&D campus in Hyderabad, aiming to double its process R&D capacity by September 2026. The project adds dedicated…
Sponsored Content See More >
Advancing Pressure Protection in Biopharma: How Integrated Bypass Technology Elevates Single-Use Pump Designby Michael Irving, Xylem In pharmaceutical and biopharmaceutical manufacturing, there is zero margin for error when it comes to process…
What sets oncology biosimilars apart: Anticipating key challenges in the development landscapeBy Kimberly Salgado, ICON plc Advancements in biologic therapies have greatly improved our ability to treat cancer over the last…
Complexity’s counterpoint: Understanding protocol optimization In recent years, the clinical research landscape has been marked by a steady rise in protocol complexity with more endpoints…
Optimizing Data Pipelines in Life Sciences with AI-Driven Integration and FHIRSponsored by Infor. Data management in life sciences is inherently complex. Data is fragmented across multiple systems — such…
Accelerating life sciences with AI This case study is sponsored by Infor. Artificial intelligence can revolutionize clinical interoperability by building bridges across data silos. Machine…
Advancing Clinical Trials and ResearchThis case study is sponsored by Infor. In the complex landscape of clinical trials and medical research, data fragmentation remains…
Multidisciplinary approaches optimize contract drug discovery
5 Key Questions in Conducting Global Usability StudiesBy Dr Bryce G Rutter, Head Noble Consulting Services Evaluating device usability throughout the product development process is crucial. A…
Leveraging HF/UX/ID Services to Optimize the Design of Combination Devices for Arthritic HandsBy Dr. Bryce G Rutter, Head of Consulting Services Arthritis changes how people grasp and manipulate an object, reducing the…
Ask the Expert: Navigating the New FDA Rules on Laboratory Developed Tests (LDTs)The U.S. FDA released a final rule to regulate laboratory developed tests (LDTs) on May 6, 2024, making it clear…
How tailored qPCR assays can unlock microbiome and precision medicine potential Sponsored by Diversigen, Inc. Quantitative Polymerase Chain Reaction (qPCR) — also known as real-time PCR — is a molecular…
Innovations in Baculovirus–Insect Cell Expression SystemsThe baculovirus–insect cell expression system—insect cells used in conjunction with the baculovirus expression vector system (BEVS)—remains a crucial technology for…
Genomics/Proteomics See More >
Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
A new foundation model called GREmLN from a Columbia and Chan Zuckerberg Biohub team, delivers superior cell-type classification with only 10.3 million parameters, outpacing rivals like the 100-million-parameter scFoundation. Released July 9 on bioRxiv, it taps gene regulatory networks to achieve a 0.929 macro F1 score on immune cell data. “Instead of using large language…
Spatial biology: Transforming our understanding of cellular environments
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
St. Jude pioneers gene editing and structural biology to advance pediatric research
Infectious Disease See More >
RSV at IDWeek 2025: Competitive expansion of preventive and therapeutic modalities
This year’s IDWeek (Oct 19-22, 2025) showcased a spectrum of therapeutics to protect against and treat Respiratory syncytial virus (RSV) infection across vulnerable populations: infants, older adults, and the immunocompromised. Once dominated by seasonal hospital surges and limited preventive options, RSV management is entering a new era characterized by durable vaccination strategies, next-generation monoclonal antibodies,…
Oncology See More >
Precision medicine made trials smarter. It also made recruitment harder.
In statistics and machine learning, there’s a tradeoff between precision and recall: tune a system to be more selective and you inevitably miss more true positives. Cancer clinical trials have stumbled into a similar trap. As oncology has shifted from tumor-type-centered studies to gene-directed approaches, eligibility criteria have grown exquisitely precise. Instead of enrolling patients…
